Table 3:
Association between Race and Receipt of HCV-viremic kidneys among HCV-seronegative recipients [D+/R−]*
| Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|
| Odds Ratio (95% CI) | |||||
| Race: Black vs White | 0.69 (0.60–0.80) | 0.96 (0.83–1.12) | 0.96 (0.83–1.12) | ||
| Race: Hispanic vs White | 0.63 (0.51–0.79) | 0.79 (0.63–0.98) | 0.89 (0.70–1.11) | ||
| Race: Asian vs White | 0.69 (0.53–0.90) | 0.75 (0.57–0.99) | 0.76 (0.58–1.01) | ||
| Gender: Male vs Female | 1.25 (1.10–1.42) | 1.28 (1.12–1.47) | 1.29 (1.13–1.47) | ||
| Age (10 years)† | 1.68 (1.59–1.77) | 1.57 (1.48–1.66) | 1.57 (1.48–1.66) | ||
| Waiting time (years) | - | 0.65 (0.63–0.67) | 0.65 (0.63–0.67) | ||
| Education Level: Grade School or Below vs High School | - | - | 0.67 (0.49–0.92) | ||
| Education Level: College or Above vs High School | - | - | 1.16 (1.02–1.31) | ||
| Blood group: A vs O | 0.64 (0.56–0.73) | 0.41 (0.36–0.47) | 0.41 (0.36–0.47) | ||
| Blood group: B vs O | 0.58 (0.49–0.70) | 0.46 (0.38–0.56) | 0.46 (0.38–0.56) | ||
| Blood group: AB vs O | 0.38 (0.29–0.51) | 0.16 (0.12–0.22) | 0.16 (0.12–0.22) | ||
| Cause of kidney failure: Hypertension vs Diabetes | 0.64 (0.55–0.74) | 0.69 (0.59–0.80) | 0.69 (0.59–0.80) | ||
| Cause of kidney failure: Glomerulonephritis vs Diabetes | 0.67 (0.56–0.82) | 0.65 (0.53–0.79) | 0.64 (0.53–0.78) | ||
| Cause of kidney failure: Congenital vs Diabetes | 0.88 (0.71–1.1) | 0.94 (0.76–1.16) | 0.93 (0.75–1.15) | ||
| Cause of kidney failure: Other vs Diabetes | 0.59 (0.49–0.72) | 0.61 (0.50–0.75) | 0.60 (0.49–0.74) | ||
| cPRA: <70 vs >70 | 4.76 (3.53–6.43) | 8.74 (6.4–12.0) | 8.69 (6.32–11.94) | ||
| Medical Insurance: Medicare vs Medicaid | 0.95 (0.72–1.24) | 1.17 (0.88–1.55) | 1.11 (0.83–1.47) | ||
| Medical Insurance: Private vs Medicaid | 1.50 (1.12–1.99) | 1.11 (0.82–1.49) | 1.03 (0.76–1.39) | ||
| Center % Black Race(>50%): Yes vs No | 2.55 (1.06–6.03) | 2.21 (0.91–5.36) | 2.23 (0.92–5.40) | ||
| Center Transplant Volume: Medium vs Low | 1.43 (0.60–3.40) | 1.40 (0.57–3.42) | 1.39 (0.57–3.40) | ||
| Center Transplant Volume: Medium-High vs Low | 2.44 (0.95–6.23) | 2.42 (0.92–6.37) | 2.40 (0.91–6.31) | ||
| Center Transplant Volume: High vs Low | 4.67 (1.51–14.50) | 4.80 (1.50–15.38) | 4.75 (1.48–15.23) | ||
| Center Utilization of PHS kidneys: Medium vs Low | 1.59 (0.55–4.57) | 1.62 (0.55–4.80) | 1.62 (0.55–4.80) | ||
| Center Utilization of PHS kidneys : Medium-High vs Low | 4.36 (1.58–11.97) | 4.33 (1.53–12.26) | 4.36 (1.54–12.34 | ||
| Center Utilization of PHS kidneys : High vs Low | 24.44 (9.44–63.29) | 27.1 (10.2–72.3) | 27.3 (10.3–72.8) | ||
*
Recipient factors associated with receiving HCV-viremic kidneys among seronegative patients are shown.
Model 1: Adjusted for donor variables: age, height, weight, ethnicity, hypertension, diabetes, cause of death, creatinine, and non-heart beating donor (DCD) and number of HLA mismatches.
Model 2: Adjusted for variables from Model1 and waiting time
Model 3: Adjusted for variables from Model 2 and education level
Abbreviations: CI: confidence interval; cPRA: calculated panel reactive antibodies; HCV: Hepatitis C; PHS: public health service; HLA: Human leukocyte antigen
†
Unit for age is 10 years i.e., odds increase per 10-year increase in age.